Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Susan L. Greenspan, Adam Brufsky, Barry C. Lembersky, +5

Journal of Clinical Oncology

The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer

G. J. van Londen, Subashan Perera, K. Vujevich, +5

Breast Cancer Research and Treatment

Breast OncologyEndocrine-related CancerHormone LevelsMedicineGynecology +9

Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur

S. L. Greenspan, K. Vujevich, C A Britton, +6

Osteoporosis International

Skeletal TraumaBone DiseaseBisphosphonate-associated Atypical FractureFracture HealingOrthopaedics +4

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial

S. L. Greenspan, K. Vujevich, Adam Brufsky, +6

Osteoporosis International

Bone DiseaseBone LossBreast OncologyBone HealthMedicine +7

Partial Meal Replacement Plan and Quality of the Diet at 1 Year: Action for Health in Diabetes (Look AHEAD) Trial

Hollie A. Raynor, Andrea Anderson, Gary D. Miller, +372

Journal of the Academy of Nutrition and Dietetics

NutritionDiabetes ManagementDiabetesPublic Health NutritionLook Ahead +4

Implementing a fracture liaison service open model of care utilizing a cloud-based tool

S. L. Greenspan, Andrea Singer, K. Vujevich, +9

Osteoporosis International

NursingHealth Care DeliveryIntegrated CarePrimary CareConnected Health +7

Effect of risedronate on hip structural geometry: A 1-year, double-blind trial in chemotherapy-induced postmenopausal women

G. J. van Londen, Subashan Perera, K. Vujevich, +3

Bone

Chemotherapy-induced Postmenopausal WomenHip Structural GeometryDouble-blind TrialBreast CancerSurgery +5

Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial

Chaithra Prasad, Susan L. Greenspan, K. Vujevich, +7

Bone

Bone DiseaseBreast OncologyBone HealthOrthopaedic SurgeryMedicine +12

The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: A 2-year trial

G. J. van Londen, Subashan Perera, K. Vujevich, +3

Bone

Bone DiseaseBone HealthHip Structural GeometryMedicineAromatase +10